Antithrombotic therapy for pregnancy loss

Human Reproduction Update

Volumn 19, Issue 6, 2013, Pages 656-673

  de Jong, Paulien G ^a   Goddijn, Mariëtte ^a   Middeldorp, Saskia ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anticoagulants; Antiphospholipid syndrome; Fetal death; Pregnancy complications; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BEMIPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; PLACEBO;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; HUMAN; INHERITED THROMBOPHILIA; LIVE BIRTH; MULTICENTER STUDY (TOPIC); PREGNANCY LOSS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPONTANEOUS ABORTION; THROMBOPHILIA; THROMBOSIS;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FETAL DEATH; PREGNANCY COMPLICATIONS; THROMBOPHILIA;

ABORTION, HABITUAL; ABORTION, SPONTANEOUS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 84880627927     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmt019     Document Type: Article

References (101)

1. Alalaf S. Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome. Arch Gynecol Obstet 2012;285:641-647.
2. ASRM. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012;98:1103-1111.
3. ASRM. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2013;99:63.
4. Badawy AM, Khiary M, Sherif LS, Hassan M, Ragab A, Abdelall I. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol 2008;28:280-284.
5. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:209-220.
6. Bank I, Libourel EJ, Middeldorp S, Van Der Meer J, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost 2003;1:859-861.
7. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e691S-e736S.
8. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000;83:693-697.
9. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005;3:227-229.
10. Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999;14:2868-2871.
11. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003;1:433-438.
12. Chauleur C, Galanaud JP, Alonso S, Cochery-Nouvellon E, Balducchi JP, Mares P, Fabbro-Peray P, Gris JC. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 2010;8:699-706.
13. Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, Whyte S, Greer IA. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010;115:4162-4167.
14. Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997;12:387-389.
15. Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, Farquharson RG. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost 2010;8:2208-2213.
16. Coppens M, Folkeringa N, Teune MJ, Hamulyak K, Van Der Meer J, Prins MH, Buller HR, Middeldorp S. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost 2007;5:1444-1448.
17. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing group of the antiphospholipid antibody treatment trial. Am J Obstet Gynecol 1997;176:1099-1100.
18. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 2004;364:911-912.
19. de Groot PG, Meijers JC. beta(2) -Glycoprotein I: evolution, structure and function. J Thromb Haemost 2011;9:1275-1284.
20. de Jong PG, Goddijn M, Middeldorp S. Testing for inherited thrombophilia in recurrent miscarriage. Semin Reprod Med 2011;29:540-547.
21. de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2013 (submitted).
22. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood 2009;114:2367-2374.
23. Dendrinos S, Makrakis E, Botsis D, Chassiakos D, Baka S, Creatsas G. A study of pregnancy loss in 352 women with recurrent miscarriages. Arch Gynecol Obstet 2005;271:235-239.
24. Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De CS, Caruso A. Lowmolecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999;14:489-495.
25. Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006;86:362-366.
26. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005; CD002859.
27. Esmon CT, Taylor FB Jr, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991;66:160-165.
28. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-413.
29. Farquharson RG, Jauniaux E, Exalto N. Updated and revised nomenclature for description of early pregnancy events. Hum Reprod 2005;20:3008-3011.
30. Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey AA, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008; 278:33-38.
31. Folkeringa N, Brouwer JL, Korteweg FJ, Veeger NJ, Erwich JJ, Holm JP, Van Der Meer J. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007;136:656-661.
32. Fouda UM, Sayed AM, Ramadan DI, Fouda IM. Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome. J Obstet Gynaecol 2010;30:842-846.
33. Fouda UM, Sayed AM, Abdou AM, Ramadan DI, Fouda IM, Zaki MM. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet 2011; 112:211-215.
34. Giancotti A, La Torre R, Spagnuolo A, D'Ambrosio V, Cerekja A, Piazze J, Chistolini A. Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. J Matern Fetal Neonatal Med 2012;25:1191-1194.
35. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibodyinduced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222-1226.
36. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit 2006; 12:CR132-CR136.
37. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-407.
38. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103:3695-3699.
39. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:53S-70S.
40. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
41. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-220.
42. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-489.
43. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003;9:331-337.
44. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010; 93:1234-1243.
45. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006;21:2216-2222.
46. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362:1586-1596.
47. Klock SC, Chang G, Hiley A, Hill J. Psychological distress among women with recurrent spontaneous abortion. Psychosomatics 1997;38:503-507.
48. Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, Eldor A. Lowmolecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001;20:35-44.
49. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-1589.
50. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996;35:402-407.
51. Kwak-Kim J, Yang KM, Gilman-Sachs A. Recurrent pregnancy loss: a disease of inflammation and coagulation. J Obstet Gynaecol Res 2009;35:609-622.
52. Langer R, Schreyer P, Bukovsky I, Caspi E. Adjuvant anticoagulant therapy in repeated fetal loss. Harefuah 1980;99:65-67.
53. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, Kingdom JC, Barrett J, Gent M. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009;36:279-287.
54. Laude I, Rongieres-Bertrand C, Boyer-Neumann C, Wolf M, Mairovitz V, Hugel B, Freyssinet JM, Frydman R, Meyer D, Eschwege V. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001;85:18-21.
55. Leduc L, Dubois E, Takser L, Rey E, David M. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can 2007;29:787-793.
56. Lindqvist PG, Merlo J. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence? J Thromb Haemost 2005;3:221-223.
57. Lindqvist PG, Merlo J. The natural course of women with recurrent fetal loss. J Thromb Haemost 2006;4:896-897.
58. Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999;81:532-537.
59. Lockshin MD. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost 1999;82:641-648.
60. Lok IH, Neugebauer R. Psychological morbidity following miscarriage. Best Pract Res Clin Obstet Gynaecol 2007;21:229-247.
61. Lund M, Nielsen HS, Hviid TV, Steffensen R, Nyboe AA, Christiansen OB. Hereditary thrombophilia and recurrent pregnancy loss: a retrospective cohort study of pregnancy outcome and obstetric complications. Hum Reprod 2010; 25:2978-2984.
62. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010; 49:281-288.
63. Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyak K, Prins MH, Buller HR, Van Der Meer J. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130:736-739.
64. Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost 2007;5(Suppl 1):276-282.
65. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 2007; 33:563-572.
66. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
67. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005;83:684-690.
68. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. Br Med J 2000; 320:1708-1712.
69. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006;33:2214-2221.
70. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000;183:1008-1012.
71. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-916.
72. Quenby S, Mountfield S, Cartwright JE, Whitley GS, Vince G. Effects of low-molecular-weight and unfractionated heparin on trophoblast function. Obstet Gynecol 2004;104:354-361.
73. Quenby S, Mountfield S, Cartwright JE, Whitley GS, Chamley L, Vince G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 2005;83:691-698.
74. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301-3304.
75. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314:253-257.
76. Rai R, Backos M, Baxter N, Chilcott I, Regan L. Recurrent miscarriage-an aspirin a day?. Hum Reprod 2000;15:2220-2223.
77. Rai R, Backos M, Elgaddal S, Shlebak A, Regan L. Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies. Hum Reprod 2002; 17:442-445.
78. Rand JH, Wu XX, Quinn AS, Chen PP, McCrae KR, Bovill EG, Taatjes DJ. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003;163:1193-1200.
79. Rand JH, Wu XX, Lapinski R, van Heerde WL, Reutelingsperger CP, Chen PP, Ortel TL. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004;104:2783-2790.
80. Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:839-854.
81. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a metaanalysis. Lancet 2003;361:901-908.
82. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171-196.
83. Rodger M. Important publication missing key information. Blood 2004;104: 3413-3414.
84. Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene MK, Greer I. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 2008;112:320-324.
85. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No 17. The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage. RCOG. 2011.
86. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61(Suppl 2):ii46-ii50.
87. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996;75:387-388.
88. Sierra S, Stephenson M. Genetics of recurrent pregnancy loss. Semin Reprod Med 2006;24:17-24.
89. Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H. Maternal Par4, platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. Blood 2008;112:585-591.
90. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, Ensom MH. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;26:729-734.
91. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
92. Stirrat GM. Recurrent miscarriage. Lancet 1990;336:673-675.
93. Sugiura-Ogasawara M, Ozaki Y, Nakanishi T, Sato T, Suzumori N, Kumagai K. Occasional antiphospholipid antibody positive patients with recurrent pregnancy loss also merit aspirin therapy: a retrospective cohort-control study. Am J Reprod Immunol 2008;59:235-241.
94. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005;11:7003-7011.
95. Tulppala M, Marttunen M, Soderstrom-Anttila V, Foudila T, Ailus K, Palosuo T, Ylikorkala O. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997;12: 1567-1572.
96. van den Boogaard E, Kaandorp SP, Franssen MT, Mol BW, Leschot NJ, Wouters CH, van Hylckama Vlieg A, Korevaar JC, Goddijn M. Consecutive or non-consecutive recurrent miscarriage: is there any difference in carrier status? Hum Reprod 2010;25:1411-1414.
97. van den Boogaard E, Cohn DM, Korevaar JC, Dawood F, Vissenberg R, Middeldorp S, Goddijn M, Farquharson RG. Number and sequence of preceding miscarriages and maternal age for the prediction of antiphospholipid syndrome in women with recurrent miscarriage. Fertil Steril 2013;99: 188-192.
98. Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KW, Kaaja RJ. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011;105:295-301.
99. Zegers-Hochschild F, Adamson GD, de MJ, Ishihara O, Mansour R, Nygren K, Sullivan E, van der Poel S. The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary on ART terminology, 2009. Hum Reprod 2009;24:2683-2687.
100. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010;115:1256-1262.
101. Zolghadri J, Ahmadpour F, Momtahan M, Tavana Z, Foroughinia L. Evaluation of the efficacy of aspirin and low molecular weight heparin in patients with unexplained recurrent spontaneous abortions. Iran Red Crescent Med J 2010; 12:548-552.